The Role of Endogenous GIP in Glycosis Metabolism During Fasting

Launched by FREDERIKKE KOEFOED-HANSEN · Apr 11, 2024

Keywords

ClinConnect Summary

This research project investigates the effects endogenous GIP has in the body of healthy, overweight people. Two trial days will be held. The participant will receive intravenous infusion of either GIP\[3-30\]NH2 (800 pmol/kg/min) or placebo (saline) in a randomized order. After 20 minutes, GIP\[3-30\]NH2 is expected to have maximum effect. On time of 180 minutes, an ad libitum meal is served, which is consumed during continued infusion. When the participant is comfortably full, the infusion is turned off and the trial day ends. During the day, the participant assesses and notes on standard...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18-70 years
• • BMI \> 30 kg/m2
• • Body fat percentage \> 25 % for men og \> 35 % for women
• Exclusion Criteria:
• • Type 1 diabetes and/or type 2 diabetes diagnosis
• • Other chronic condition
• • Treatment with medications or supplements that cannot be paused for 12 hours
• • \> 14 units of alcohol weekly or drug abuse
• • Circulating liver enzymes (alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT)) ≥ 2 × normal value
• • Renal impairment (eGFR \< 90 or creatinine level above the reference range)
• • Uncontrolled high resting blood pressure (above 140/90 mmHg)
• • Low blood percentage (hemoglobin \< reference range (different for women and men))
• • Special diet or planned weight change within the trial period
• • Any disease/condition that investigators believe will interfere with study participation